Callan Family Office LLC Purchases Shares of 22,183 Fresenius Medical Care AG (NYSE:FMS)

Callan Family Office LLC purchased a new stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 22,183 shares of the company's stock, valued at approximately $502,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FMS. Smartleaf Asset Management LLC raised its holdings in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after acquiring an additional 806 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Fresenius Medical Care during the third quarter worth about $38,000. Jones Financial Companies Lllp raised its stake in Fresenius Medical Care by 80.5% during the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock worth $102,000 after purchasing an additional 2,012 shares during the period. Venturi Wealth Management LLC boosted its holdings in Fresenius Medical Care by 1,045.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company's stock valued at $112,000 after purchasing an additional 4,800 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Fresenius Medical Care by 43.3% in the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company's stock valued at $162,000 after buying an additional 2,166 shares during the period. Institutional investors and hedge funds own 8.37% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on FMS shares. Truist Financial lifted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Bank of America raised Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th.

Remove Ads

Fresenius Medical Care Trading Up 2.3 %

Fresenius Medical Care stock traded up $0.55 during trading on Tuesday, hitting $24.31. The company had a trading volume of 233,355 shares, compared to its average volume of 268,245. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company's 50 day simple moving average is $23.55 and its 200-day simple moving average is $22.08. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.25. The stock has a market cap of $14.27 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.